{"id":259644,"date":"2026-05-29T07:48:19","date_gmt":"2026-05-29T07:48:19","guid":{"rendered":"https:\/\/www.europesays.com\/se\/259644\/"},"modified":"2026-05-29T07:48:19","modified_gmt":"2026-05-29T07:48:19","slug":"cantargia-genomfor-foretradesemission-pa-124-miljoner-kronor-ingar-aven-laneavtal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/259644\/","title":{"rendered":"Cantargia genomf\u00f6r f\u00f6retr\u00e4desemission p\u00e5 124 miljoner kronor, ing\u00e5r \u00e4ven l\u00e5neavtal"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Forskningsbolaget Cantargias styrelse har beslutat att genomf\u00f6ra en f\u00f6retr\u00e4desemission p\u00e5 124 miljoner kronor f\u00f6re emissionskostnader p\u00e5 17 miljoner kronor. Bolaget ing\u00e5r \u00e4ven ett l\u00e5neavtal p\u00e5 upp till 75 miljoner kronor. Det framg\u00e5r av ett pressmeddelande.\n <\/p>\n<p>F\u00f6retr\u00e4desemissionen och l\u00e5neavtalet genomf\u00f6rs fr\u00e4mst f\u00f6r att s\u00e4kra finansiering f\u00f6r inledande av en fas Ib-studie d\u00e4r nadunolimab kombineras med en RAS-h\u00e4mmare samt fortsatt utveckling och positionering avseende bukspottk\u00f6rtelcancer, utvidgande av den p\u00e5g\u00e5ende kliniska fas Ib\/IIa-studien och f\u00f6rberedelser av en fas IIb-studie avseende myelodysplastiskt syndrom\/akut myeloisk leukemi.\n <\/p>\n<p>F\u00f6retr\u00e4desemissionen t\u00e4cks av teckningsf\u00f6rbindelser fr\u00e5n befintliga aktie\u00e4gare, d\u00e4ribland vissa styrelseledam\u00f6ter och ledande befattningshavare, samt ett garanti\u00e5tagande uppg\u00e5ende till 75 miljoner kronor, motsvarande 60,3 procent av emissionsvolymen.\n <\/p>\n<p>Villkoren i emissionen \u00e4r 2:9, inneb\u00e4rande att nio befintliga aktier ger r\u00e4tt att teckna tv\u00e5 nya aktier till teckningskursen 2,25 kronor per aktie. Sista dag f\u00f6r handel i aktien inklusive teckningsr\u00e4tt \u00e4r den 2 juni och aktien handlas exklusive teckningsr\u00e4tt den 3 juni. Teckningstiden l\u00f6per fr\u00e5n 8 till 22 juni och handel med teckningsr\u00e4tter sker den 8 till 16 juni.\n <\/p>\n<p>Cantargia har \u00e4ven ing\u00e5tt ett l\u00e5neavtal med Fenja Capital II, som kommer att tillhandah\u00e5lla ett l\u00e5n p\u00e5 upp till 75 miljoner kronor. Cantargia har som en del av l\u00e5neavtalet \u00e5tagit sig att vederlagsfritt emittera teckningsoptioner till Fenja Capital.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Henrik \u00d6hlin<br \/>\n <br class=\"col-start-2\"\/><br \/>\n henrik.ohlin@finwire.se, 0703-21 06 99<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Forskningsbolaget Cantargias styrelse har beslutat att genomf\u00f6ra en f\u00f6retr\u00e4desemission p\u00e5 124 miljoner kronor f\u00f6re emissionskostnader p\u00e5 17 miljoner&hellip;\n","protected":false},"author":2,"featured_media":259645,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[5],"tags":[22,23,11415,26,27,17,21,24,25,28,29,15,16,18,34,31,33,32,30,19,20],"class_list":["post-259644","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rubriker","tag-breaking-news","tag-breakingnews","tag-cantargia","tag-featured-news","tag-featurednews","tag-headlines","tag-huvudnyheter","tag-latest-news","tag-latestnews","tag-main-news","tag-mainnews","tag-news","tag-nyheter","tag-rubriker","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-top-stories","tag-topstories"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116656767316317332","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/259644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=259644"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/259644\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/259645"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=259644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=259644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=259644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}